Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SHR-A1811 + adebrelimab versus toripalimab + nab-paclitaxel in PD-L1-positive unresectable locally recurrent or metastatic triple-negative breast cancer
CTR20253073Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan, adebrelimab, toripalimab, paclitaxel in triple-negative breast cancer (TNBC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2025; status: active.
02
Drugs
trastuzumab rezetecanadebrelimabtoripalimabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20253073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253073.